Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by LENZ Therapeutics, Inc.
LENZ Therapeutics to Participate in Upcoming Investor Conferences
November 12, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
November 06, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
October 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
October 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
October 21, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
September 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
August 12, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
July 15, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
June 10, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 08, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
May 01, 2024
From
Lenz Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LENZ
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
April 03, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
Tickers
LENZ
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
April 02, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
Tickers
LENZ
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
March 21, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.